Nektar Therapeutics Secures Over $500M in Capital, Funds Phase 3 Trials Despite Q4 Losses

summarizeSummary

Nektar Therapeutics reported a decline in Q4 2025 revenue and increased net loss, but announced a significantly strengthened financial position from recent capital raises totaling over $500 million, enabling the advancement of its lead clinical programs.

check_boxKey Events

• Q4 and Full Year 2025 Financial Results Reported

  Nektar Therapeutics reported Q4 2025 revenue of $21.8 million, down from $29.2 million in Q4 2024, and a net loss of $36.1 million ($1.78 per share) compared to net income of $7.3 million ($0.52 per share) in the prior year quarter. Full year 2025 revenue was $55.2 million, down from $98.4 million in 2024, with a net loss of $164.1 million ($9.73 per share).

• Over $500 Million in New Capital Secured

  The company announced a significantly strengthened financial position, with cash and investments on December 31, 2025, at $245.8 million. This figure excludes approximately $432 million in net proceeds from a public offering completed in February 2026 and an additional $44 million from at-the-market (ATM) sales in February and March 2026, totaling over $500 million in new capital.

• Key Pipeline Programs Advancing to Phase 3

  Nektar Therapeutics plans to initiate Phase 3 studies for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in Q2 2026. The company also highlighted positive Phase 2 data readouts for rezpegaldesleukin in atopic dermatitis and alopecia areata, and a new research collaboration with UCSF for NKTR-0165.

auto_awesomeAnalysis

This 8-K filing, while reporting a decline in Q4 2025 revenue and an increased net loss, highlights a critical strengthening of Nektar Therapeutics' financial position. The successful completion of a $460 million public offering and an additional $44 million from at-the-market sales provides substantial capital, significantly extending the company's cash runway. This funding is crucial for a clinical-stage biotech, enabling the planned initiation of Phase 3 studies for rezpegaldesleukin in atopic dermatitis and other pipeline advancements. Investors should focus on the company's enhanced ability to fund its key clinical programs, which de-risks future development despite the short-term financial performance.